trending Market Intelligence /marketintelligence/en/news-insights/trending/MgMmF20V_yLhaw3CNC9qWQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Accurexa, Medisun enter license agreement for cancer treatment technology

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Accurexa, Medisun enter license agreement for cancer treatment technology

Accurexa Inc. entered into a license agreement with Hong Kong-based Medisun Holdings Ltd., which granted Accurexa a nonexclusive license to use Medisun's Natural Killer cell technology.

This license agreement applies to the rest of the world other than Greater China and U.S. because these regions were covered under a previous license agreement entered between the companies.

As consideration for the license, Accurexa agreed to issue to Medisun or its nominees 30 million common shares.

Medisun has developed the cell technology for the treatment of cancer. It is clinically used to treat cancer patients at Medisun's network clinical facilities.

The license provides that Medisun will provide Accurexa any relevant technical advice and support from time to time as required by the company during the term of the agreement.